Thematic Intelligence: Microbiome-Based Therapeutics

Thematic Intelligence: Microbiome-Based Therapeutics Summary The microbiome, encompassing a vast array of microorganisms inhibiting the human body, has garnered significant attention for its role in health and disease. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics’ Rebyota and Seres Therapeutics’ Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions. However, while awareness of the microbiome seems to be growing and acceptance of its potential benefits is increasing, adoption remains varied. In this report, GlobalData assesses the current landscape of microbiome-based therapeutics in the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan) and examines healthcare professionals’ opinions and utilization of these therapies. Scope Study objectives - - Examine the current utilization practices of microbiome-based therapies - Assess the barriers and opportunities associated with the use of microbiome-based therapies - Measure expected use of microbiome-based therapies in the future - Identify major players in the microbiome industry - Analyze market trends and deal-making activities in the microbiome sector - Overview marketed and pipeline products Reasons to Buy - Develop business strategies by understanding the trends shaping and driving the global microbiome-targeting therapy market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global microbiome-targeting therapy market in the future. - Design your development strategy through a review of potential novel targets or combinations across indications. - Understand the challenges and strategies impacting the development of microbiome-targeting therapy agents in preclinical studies and clinical trials. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the classes of microbiome-targeting therapy and indications that present maximum opportunities for consolidations, investments, and strategic partnerships.